Trexquant Investment LP Sells 168,085 Shares of Pediatrix Medical Group, Inc. $MD

Key Points

• Trexquant Investment LP reduced its stake in Pediatrix Medical Group by 39.0%, owning approximately 263,145 shares valued at $3.81 million after selling 168,085 shares in Q1.
• Pediatrix Medical Group reported earnings per share (EPS) of $0.53, exceeding analysts' expectations of $0.42, with quarterly revenue at $468.84 million.
• Currently, Pediatrix Medical Group's stock has a Moderate Buy rating with an average target price of $16.75 according to sell-side analysts.

Trexquant Investment LP decreased its position in Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 39.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 263,145 shares of the company's stock after selling 168,085 shares during the period. Trexquant Investment LP owned 0.31% of Pediatrix Medical Group worth $3,813,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in MD. California State Teachers Retirement System boosted its holdings in Pediatrix Medical Group by 0.9% during the fourth quarter. California State Teachers Retirement System now owns 80,327 shares of the company's stock worth $1,054,000 after buying an additional 752 shares during the last quarter. AlphaQuest LLC boosted its holdings in Pediatrix Medical Group by 16.0% during the first quarter. AlphaQuest LLC now owns 5,877 shares of the company's stock worth $85,000 after buying an additional 811 shares during the last quarter. SummerHaven Investment Management LLC boosted its holdings in Pediatrix Medical Group by 0.9% during the first quarter. SummerHaven Investment Management LLC now owns 112,327 shares of the company's stock worth $1,628,000 after buying an additional 1,028 shares during the last quarter. Natixis Advisors LLC boosted its holdings in Pediatrix Medical Group by 8.1% during the first quarter. Natixis Advisors LLC now owns 19,156 shares of the company's stock worth $278,000 after buying an additional 1,435 shares during the last quarter. Finally, GAMMA Investing LLC boosted its holdings in Pediatrix Medical Group by 219.5% during the first quarter. GAMMA Investing LLC now owns 2,569 shares of the company's stock worth $37,000 after buying an additional 1,765 shares during the last quarter. Institutional investors own 97.71% of the company's stock.

Pediatrix Medical Group Stock Up 0.3%

Shares of NYSE MD traded up $0.05 during mid-day trading on Friday, reaching $17.06. 1,045,640 shares of the company's stock were exchanged, compared to its average volume of 796,330. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of 13.22 and a beta of 1.30. The company has a current ratio of 1.80, a quick ratio of 1.80 and a debt-to-equity ratio of 0.70. The business has a fifty day simple moving average of $14.46 and a 200 day simple moving average of $14.14. Pediatrix Medical Group, Inc. has a twelve month low of $10.06 and a twelve month high of $17.67.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.53 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.42 by $0.11. Pediatrix Medical Group had a return on equity of 18.94% and a net margin of 5.66%.The business had revenue of $468.84 million for the quarter, compared to analyst estimates of $464.37 million. During the same quarter last year, the firm earned $0.34 EPS. Pediatrix Medical Group's revenue for the quarter was down 7.1% compared to the same quarter last year. As a group, equities analysts expect that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MD has been the topic of a number of recent analyst reports. UBS Group raised their target price on Pediatrix Medical Group from $16.00 to $16.50 and gave the stock a "neutral" rating in a report on Thursday, August 14th. Leerink Partners raised their target price on Pediatrix Medical Group from $14.50 to $17.00 and gave the stock a "market perform" rating in a report on Friday. Finally, Zacks Research upgraded Pediatrix Medical Group to a "strong-buy" rating in a report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Pediatrix Medical Group has a consensus rating of "Moderate Buy" and an average target price of $16.79.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.